Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.61 |
| ▸ | RAB9A | P51151 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | HPGD | P15428 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28116783 | 0.86 | NPC1 (0.72) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL784353 | 0.81 | NPC1 (0.66) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29825055 | 0.81 | NPC1 (0.66) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31677102 | 0.81 | NPC1 (0.66) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL227743 | 0.80 | NPC1 (0.78) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| Benzene SCHEMBL29179821 | 0.80 | RAB9A (0.64) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3541718 | 0.79 | FGFR1 (0.68) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29093710 | 0.79 | PDE5A (0.61) | FGFR1FLT1BCHE | |
| SCHEMBL29733506 | 0.78 | KIF11 (0.63) | ALDH1A1HSD17B10BCHE | |
| SCHEMBL208113 | 0.78 | KIF11 (0.63) | ALDH1A1HSD17B10BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8974923-B2 | Organic compound and organic light-emitting device having the same | CANON KABUSHIKI KAISHA (JP) | 2015-03-10 | — | — | US | claimed |
| US-20130001537-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-01-03 | — | — | US | claimed |
| WO-2011122381-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2011-10-06 | — | — | WO | claimed |
| CN-111171004-B | (E) Preparation method of 2- (2- (9-alkyl) carbazole-3-) vinyl-benzimidazole | 陕西科技大学 | 2021-08-24 | — | — | CN | disclosed |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-04 | — | — | US | disclosed |
| CN-111171004-A | (E) Preparation method of 2- (2- (9-alkyl) carbazole-3-) vinyl-benzimidazole | 陕西科技大学 | 2020-05-19 | — | — | CN | disclosed |
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-8974923-B2 | Organic compound and organic light-emitting device having the same | CANON KABUSHIKI KAISHA (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8974923-B2 | Organic compound and organic light-emitting device having the same | CANON KABUSHIKI KAISHA (JP) | 2015-03-10 | — | — | US | disclosed |
| US-20130001537-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20130001537-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-01-03 | — | — | US | disclosed |
| JP-2011213650-A | NEW ORGANIC COMPOUND AND ORGANIC LUMINESCENT DEVICE HAVING THE SAME | CANON INC | 2011-10-27 | — | — | JP | disclosed |
| WO-2011122381-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011122381-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130001537-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE SAME | ORC3, CRY1, TRPA1 | NPC1 1265/4885RAB9A 2792/4885ALDH1A1 273/4885 |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | PTGER4, PTGER1, PTGER2 | NPC1 1969/4885RAB9A 4037/4885ALDH1A1 560/4885 |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, EPB41 | NPC1 1558/4885RAB9A 4004/4885ALDH1A1 511/4885 |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, PTGER2 | NPC1 1816/4885RAB9A 4328/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.